Recent developments and therapeutic strategies against hepatocellular carcinoma

Mark Yarchoan; Parul Agarwal; Augusto Villanueva; Shuyun Rao; Laura A. Dawson; Josep M. Llovet; Richard S. Finn; John D. Groopman; Hashem B. El-Serag; Satdarshan P. Monga; Xin Wei Wang; Michael Karin; Robert E. Schwartz; Kenneth K. Tanabe; Lewis R. Roberts; Preethi H. Gunaratne; Allan Tsung; Kimberly A. Brown; Theodore S. Lawrence; Riad Salem; Amit G. Singal; Amy K. Kim; Atoosa Rabiee; Linda Resar; Yujin Hoshida; Aiwu Ruth He; Kalpana Ghoshal; Patrick B. Ryan; Elizabeth M. Jaffee; Chandan Guha; Lopa Mishra; C. Norman Coleman; Mansoor M. Ahmed

doi:10.1158/0008-5472.CAN-19-0803

Recent developments and therapeutic strategies against hepatocellular carcinoma

Mark Yarchoan, Parul Agarwal, Augusto Villanueva, Shuyun Rao, Laura A. Dawson, Josep M. Llovet, Richard S. Finn, John D. Groopman, Hashem B. El-Serag, Satdarshan P. Monga, Xin Wei Wang, Michael Karin, Robert E. Schwartz, Kenneth K. Tanabe, Lewis R. Roberts, Preethi H. Gunaratne, Allan Tsung, Kimberly A. Brown, Theodore S. Lawrence, Riad SalemAmit G. Singal, Amy K. Kim, Atoosa Rabiee, Linda Resar, Yujin Hoshida, Aiwu Ruth He, Kalpana Ghoshal, Patrick B. Ryan, Elizabeth M. Jaffee, Chandan Guha, Lopa Mishra, C. Norman Coleman, Mansoor M. Ahmed

Research output: Contribution to journal › Article › peer-review

104 Scopus citations

Abstract

Hepatocellular carcinoma (HCC) has emerged as a major cause of cancer deaths globally. The landscape of systemic therapy has recently changed, with six additional systemic agents either approved or awaiting approval for advanced stage HCC. While these agents have the potential to improve outcomes, a survival increase of 2-5 months remains poor and falls short of what has been achieved in many other solid tumor types. The roles of genomics, underlying cirrhosis, and optimal use of treatment strategies that include radiation, liver transplantation, and surgery remain unanswered. Here, we discuss new treatment opportunities, controversies, and future directions in managing HCC.

Original language	English
Pages (from-to)	4326-4330
Number of pages	5
Journal	Cancer Research
Volume	79
Issue number	17
DOIs	https://doi.org/10.1158/0008-5472.CAN-19-0803
State	Published - 1 Sep 2019

Access to Document

10.1158/0008-5472.CAN-19-0803

Cite this

Yarchoan, M., Agarwal, P., Villanueva, A., Rao, S., Dawson, L. A., Llovet, J. M., Finn, R. S., Groopman, J. D., El-Serag, H. B., Monga, S. P., Wang, X. W., Karin, M., Schwartz, R. E., Tanabe, K. K., Roberts, L. R., Gunaratne, P. H., Tsung, A., Brown, K. A., Lawrence, T. S., ... Ahmed, M. M. (2019). Recent developments and therapeutic strategies against hepatocellular carcinoma. Cancer Research, 79(17), 4326-4330. https://doi.org/10.1158/0008-5472.CAN-19-0803

@article{a0d6f3fe94834a7a87e30b8da0251bcc,

title = "Recent developments and therapeutic strategies against hepatocellular carcinoma",

abstract = "Hepatocellular carcinoma (HCC) has emerged as a major cause of cancer deaths globally. The landscape of systemic therapy has recently changed, with six additional systemic agents either approved or awaiting approval for advanced stage HCC. While these agents have the potential to improve outcomes, a survival increase of 2-5 months remains poor and falls short of what has been achieved in many other solid tumor types. The roles of genomics, underlying cirrhosis, and optimal use of treatment strategies that include radiation, liver transplantation, and surgery remain unanswered. Here, we discuss new treatment opportunities, controversies, and future directions in managing HCC.",

author = "Mark Yarchoan and Parul Agarwal and Augusto Villanueva and Shuyun Rao and Dawson, {Laura A.} and Llovet, {Josep M.} and Finn, {Richard S.} and Groopman, {John D.} and El-Serag, {Hashem B.} and Monga, {Satdarshan P.} and Wang, {Xin Wei} and Michael Karin and Schwartz, {Robert E.} and Tanabe, {Kenneth K.} and Roberts, {Lewis R.} and Gunaratne, {Preethi H.} and Allan Tsung and Brown, {Kimberly A.} and Lawrence, {Theodore S.} and Riad Salem and Singal, {Amit G.} and Kim, {Amy K.} and Atoosa Rabiee and Linda Resar and Yujin Hoshida and He, {Aiwu Ruth} and Kalpana Ghoshal and Ryan, {Patrick B.} and Jaffee, {Elizabeth M.} and Chandan Guha and Lopa Mishra and {Norman Coleman}, C. and Ahmed, {Mansoor M.}",

note = "Publisher Copyright: {\textcopyright} 2019 American Association for Cancer Research.",

year = "2019",

month = sep,

day = "1",

doi = "10.1158/0008-5472.CAN-19-0803",

language = "English",

volume = "79",

pages = "4326--4330",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research Inc.",

number = "17",

}

Yarchoan, M, Agarwal, P, Villanueva, A, Rao, S, Dawson, LA, Llovet, JM, Finn, RS, Groopman, JD, El-Serag, HB, Monga, SP, Wang, XW, Karin, M, Schwartz, RE, Tanabe, KK, Roberts, LR, Gunaratne, PH, Tsung, A, Brown, KA, Lawrence, TS, Salem, R, Singal, AG, Kim, AK, Rabiee, A, Resar, L, Hoshida, Y, He, AR, Ghoshal, K, Ryan, PB, Jaffee, EM, Guha, C, Mishra, L, Norman Coleman, C & Ahmed, MM 2019, 'Recent developments and therapeutic strategies against hepatocellular carcinoma', Cancer Research, vol. 79, no. 17, pp. 4326-4330. https://doi.org/10.1158/0008-5472.CAN-19-0803

TY - JOUR

T1 - Recent developments and therapeutic strategies against hepatocellular carcinoma

AU - Yarchoan, Mark

AU - Agarwal, Parul

AU - Villanueva, Augusto

AU - Rao, Shuyun

AU - Dawson, Laura A.

AU - Llovet, Josep M.

AU - Finn, Richard S.

AU - Groopman, John D.

AU - El-Serag, Hashem B.

AU - Monga, Satdarshan P.

AU - Wang, Xin Wei

AU - Karin, Michael

AU - Schwartz, Robert E.

AU - Tanabe, Kenneth K.

AU - Roberts, Lewis R.

AU - Gunaratne, Preethi H.

AU - Tsung, Allan

AU - Brown, Kimberly A.

AU - Lawrence, Theodore S.

AU - Salem, Riad

AU - Singal, Amit G.

AU - Kim, Amy K.

AU - Rabiee, Atoosa

AU - Resar, Linda

AU - Hoshida, Yujin

AU - He, Aiwu Ruth

AU - Ghoshal, Kalpana

AU - Ryan, Patrick B.

AU - Jaffee, Elizabeth M.

AU - Guha, Chandan

AU - Mishra, Lopa

AU - Norman Coleman, C.

AU - Ahmed, Mansoor M.

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Hepatocellular carcinoma (HCC) has emerged as a major cause of cancer deaths globally. The landscape of systemic therapy has recently changed, with six additional systemic agents either approved or awaiting approval for advanced stage HCC. While these agents have the potential to improve outcomes, a survival increase of 2-5 months remains poor and falls short of what has been achieved in many other solid tumor types. The roles of genomics, underlying cirrhosis, and optimal use of treatment strategies that include radiation, liver transplantation, and surgery remain unanswered. Here, we discuss new treatment opportunities, controversies, and future directions in managing HCC.

AB - Hepatocellular carcinoma (HCC) has emerged as a major cause of cancer deaths globally. The landscape of systemic therapy has recently changed, with six additional systemic agents either approved or awaiting approval for advanced stage HCC. While these agents have the potential to improve outcomes, a survival increase of 2-5 months remains poor and falls short of what has been achieved in many other solid tumor types. The roles of genomics, underlying cirrhosis, and optimal use of treatment strategies that include radiation, liver transplantation, and surgery remain unanswered. Here, we discuss new treatment opportunities, controversies, and future directions in managing HCC.

UR - http://www.scopus.com/inward/record.url?scp=85071762528&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-19-0803

DO - 10.1158/0008-5472.CAN-19-0803

M3 - Article

C2 - 31481419

AN - SCOPUS:85071762528

SN - 0008-5472

VL - 79

SP - 4326

EP - 4330

JO - Cancer Research

JF - Cancer Research

IS - 17

ER -

Recent developments and therapeutic strategies against hepatocellular carcinoma

Abstract

Access to Document

Fingerprint

Cite this